The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.
The conversation humorously discusses hair regrowth using PP405, with jokes about side effects and secret hair transplants. The user claims no side effects except craving cheese.
Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.
The conversation discusses a hair regrowth treatment containing Minoxidil, Procapil, Sandalore, and caffeine. The focus is on evaluating the effectiveness of this product available on eBay.
The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.
The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
A user shared their positive experience with Roots by GA, a company that creates personalized hair loss treatments based on DNA analysis, which confirmed their inability to tolerate finasteride. The user is satisfied with their progress 30 days after a hair transplant and the customized formula they received.
A 37-year-old woman with androgenetic alopecia is using spironolactone, oral and topical minoxidil, and considering PRP therapy due to lack of progress. She is unable to obtain finasteride, dutasteride, or bicalutamide and is exploring other options like Clascoterone and RU58841.
PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.
The user experienced temporary peach fuzz growth using a product with procapil and later tried minoxidil and finasteride without significant results. Their boyfriend has used minoxidil and finasteride consistently for over five years with sparse hair improvement.
People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.
A user is attempting to reformulate a topical gel using PP-405 for hair loss, aiming to enhance its effectiveness with additional compounds. They discuss the potential of PP-405 compared to other treatments like Minoxidil and GT20029, and emphasize the importance of proper formulation for efficacy.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.
Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.
PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.
Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.
RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.
PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.
Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.
The user shared progress on hair regrowth after a third verteporfin procedure, using oral dutasteride, extended-release oral minoxidil, and occasional microneedling. The results were positively received by others.
Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.
People are skeptical about the effectiveness and availability of pp405 for hair regrowth, suggesting to use finasteride and minoxidil in the meantime. Some believe pp405 could offer significant regrowth, but it may take years before it's available.
Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.
The user reported progress in hair regrowth after 3 months using finasteride, biotin, and minoxidil, with no sexual side effects. Most responses noted significant improvement, encouraging continued use for full results.
The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.